<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893293</url>
  </required_header>
  <id_info>
    <org_study_id>20253</org_study_id>
    <nct_id>NCT02893293</nct_id>
  </id_info>
  <brief_title>Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI</brief_title>
  <official_title>Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the project is to evaluate osteonecrosis before and after decompression surgery
      with ferumoxytol-enhanced MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the project is to evaluate osteonecrosis before and after decompression surgery
      with ferumoxytol-enhanced MRI.

      The investigators approach relies on the FDA-approved iron supplement ferumoxytol (Feraheme),
      which is used off label as a contrast agent for MRI. Ferumoxytol is composed of iron oxide
      nanoparticles, which provide a strong T1- and T2-signal on magnetic resonance (MR) images and
      are taken up by cells in bone marrow.

      20 patients will undergo MRI before and after decompression surgery and transplantation of
      bone marrow derived cells. 10 patients will receive a single intravenous injection of
      ferumoxytol prior to their surgery. 10 additional patients will serve as untreated controls.
      The investigators hypothesize that MR images after intravenous injection of ferumoxytol will
      improve lesion detection and allow to track transplanted bone marrow cells. MR imaging
      findings will be correlated with clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of treatment response to decompression surgery and stem cell transplant</measure>
    <time_frame>one year</time_frame>
    <description>Evaluation of progression of osteonecrosis via scale 1-4, bone marrow edema, collapse of subchondral fractures.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Osteonecrosis</condition>
  <arm_group>
    <arm_group_label>Ferumoxytol-enhanced MRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ferumoxytol enhanced MRI</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol-enhanced magnetic resonance imaging</intervention_name>
    <description>Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant</description>
    <arm_group_label>Ferumoxytol-enhanced MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magentic Resonance Imaging</intervention_name>
    <description>Both arms will receive MRI</description>
    <arm_group_label>Ferumoxytol-enhanced MRI</arm_group_label>
    <arm_group_label>Non-ferumoxytol enhanced MRI</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteonecrosis

          -  planned decompression surgery with autologous stem cell transplant

        Exclusion Criteria:

          -  Contraindications for magnetic resonance imaging

          -  Hemosiderosis/hemochromatosis ( patients can still be included in the non-ferumoxytol
             arm)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Daldrup-Link, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Muehe, MD</last_name>
    <phone>650 497 8601</phone>
    <email>amuehe@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eileen Misquez</last_name>
    <phone>650 497 8601</phone>
    <email>emisquez@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Muehe</last_name>
      <phone>650-720-8601</phone>
      <email>amuehe@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Heike E Daldrup-Link, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://daldrup-link-lab.stanford.edu/</url>
  </link>
  <reference>
    <citation>Muehe AM, Feng D, von Eyben R, Luna-Fineman S, Link MP, Muthig T, Huddleston AE, Neuwelt EA, Daldrup-Link HE. Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. Invest Radiol. 2016 Apr;51(4):221-227. doi: 10.1097/RLI.0000000000000230.</citation>
    <PMID>26656202</PMID>
  </reference>
  <reference>
    <citation>Nejadnik H, Lenkov O, Gassert F, Fretwell D, Lam I, Daldrup-Link HE. Macrophage phagocytosis alters the MRI signal of ferumoxytol-labeled mesenchymal stromal cells in cartilage defects. Sci Rep. 2016 May 13;6:25897. doi: 10.1038/srep25897.</citation>
    <PMID>27174199</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Heike E Daldrup-Link</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

